We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Noninvasive Prenatal Test Launched

By LabMedica International staff writers
Posted on 21 May 2012
An innovative noninvasive test detects common fetal trisomies utilizing a directed approach to analyze cell-free DNA (cfDNA) in maternal blood.

The test is performed using a simple maternal blood draw taken at a doctor's office or patient service center, and provides the safety of screening tests with accuracy approaching that of invasive testing for common fetal trisomies. More...


The Harmony Prenatal Test, which detects common fetal trisomies such as Trisomy 21 which is associated with Down syndrome, will be offered through Laboratory Corporation of America Holdings (LabCorp, Burlington, NC, USA) and will be available at its more than 1,000 patient service centers. The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.

The Harmony Prenatal Test will be available in the United States and Canada through Integrated Genetics, a member of LabCorp's Specialty Testing Group. The test is a product of the molecular diagnostics company Ariosa Diagnostics (San Jose, CA, USA). Compared to random sequencing, directed cfDNA analysis is simpler, less costly, and more precise. It also provides individualized prenatal test results for trisomy risk.

Ken Song, MD, chief executive officer at Ariosa Diagnostics, said, "Ariosa Diagnostics is very excited to announce the official launch of the Harmony Prenatal Test and the agreement with LabCorp, which helps us deliver on the promise of bringing an affordable and accessible prenatal testing option to pregnant women and their physicians. With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies."

Mark Brecher, MD, LabCorp's chief medical officer, added, "We are pleased to be able to offer this novel, noninvasive prenatal test. Ariosa Diagnostics' Harmony Prenatal Test adds another option to LabCorp's comprehensive prenatal testing menu." Integrated Genetics is a business unit of Esoterix Genetic Laboratories (Austin, TX, USA), a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

Related Links:

Laboratory Corporation of America Holdings
Ariosa Diagnostics
Esoterix Genetic Laboratories




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.